CXCR1 and lung disorder: In the current study, we find that reparixin attenuates key inflammatory phenotypes in our preclinical mouse model of A-T lung disease, thereby indicating that antagonism of CXCR1/CXCR2 may represent an effective therapeutic strategy for this frequent cause of death in A-T patients.